Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes

“Given the large amount of overlapping cardiorenal benefits from these medications in this study, a combination of SGLT2 inhibitors and GLP-1 receptor agonist therapy is an important consideration. Because these agents differ with regard to glycemic control, weight loss, and select kidney and card...”